Literature DB >> 3193872

Experimental meningococcal meningitis in the infant rat.

K Saukkonen1.   

Abstract

Experimental infection of the infant rat could be established with intraperitoneal challenge with strains of all three meningococcal groups A, B, and C tested. 5-day-old rats were challenged with 3 different doses (10(2), 10(4), and 10(6) bacteria/animal) and the development of peritonitis, bacteraemia and meningitis detected as a function of time at 3, 6, and 9 h. Mortality was followed up to 24 h. Group B strains caused a rapidly developing and sustained high level bacteraemia and meningitis with all challenge doses. Bacteraemia and meningitis following challenge with MenA and MenC were of somewhat shorter duration and reached lower peak levels. Repeated 'rat passages' of meningococcal strains that had been kept stored for long periods markedly increased their virulence. This study shows that the infant rat model can be applied for studying pathogenesis of meningococcal bacteraemia and meningitis. Previous work from this laboratory has shown it to be suited also for studying antibody-mediated protection from this disease.

Entities:  

Mesh:

Year:  1988        PMID: 3193872     DOI: 10.1016/0882-4010(88)90070-8

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  9 in total

1.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis.

Authors:  David M Vu; Jutamas Shaughnessy; Lisa A Lewis; Sanjay Ram; Peter A Rice; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-21       Impact factor: 3.441

5.  A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.

Authors:  Kenneth T Mountzouros; Kelly A Belanger; Alan P Howell; Garvin S Bixler; Dace V Madore
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

Review 6.  Factor H and neisserial pathogenesis.

Authors:  Jo Anne Welsch; Sanjay Ram
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

7.  The meningococcal ABC-Type L-glutamate transporter GltT is necessary for the development of experimental meningitis in mice.

Authors:  Roberta Colicchio; Susanna Ricci; Florentia Lamberti; Caterina Pagliarulo; Chiara Pagliuca; Velia Braione; Tiziana Braccini; Adelfia Talà; Donatella Montanaro; Sergio Tripodi; Marcella Cintorino; Giancarlo Troncone; Cecilia Bucci; Gianni Pozzi; Carmelo B Bruni; Pietro Alifano; Paola Salvatore
Journal:  Infect Immun       Date:  2009-06-15       Impact factor: 3.441

8.  Imaging of disease dynamics during meningococcal sepsis.

Authors:  Hong Sjölinder; Ann-Beth Jonsson
Journal:  PLoS One       Date:  2007-02-21       Impact factor: 3.240

9.  Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis.

Authors:  Susanna Ricci; Denis Grandgirard; Michael Wenzel; Tiziana Braccini; Paola Salvatore; Marco R Oggioni; Stephen L Leib; Uwe Koedel
Journal:  BMC Infect Dis       Date:  2014-12-31       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.